Gilead Sciences Inc. was sued for corporate records in Delaware Wednesday by investors seeking to probe price-fixing and patent gamesmanship allegations involving its blockbuster HIV prevention drug Truvada—the same claims that have spawned multiple high-stakes legal disputes.
The lawsuit accuses Gilead of delaying generic Truvada versions through “extensive and unlawful anti-competitive schemes,” particularly “collusive licensing agreements” with potential rivals. It was filed in the Chancery Court by two shareholders.
The plaintiffs also say they want to investigate claims—raised in a patent infringement suit filed by the federal government—that Gilead is wrongly profiting off of certain government patents without sharing ...
